Clinical Trials Browser

NIH × Has results × AZD 6244 × Clear all

NCT03213691 2025-02-05

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

21 enrolled 11 charts

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2 Completed

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT01134601 2021-12-01

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Phase 1 Terminated

1 enrolled 7 charts

Gastrointestinal

Rectal Neoplasms

NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Phase 2 Completed

52 enrolled 11 charts

Cystadenocarcinoma, Serous

NCT01222689 2020-07-31

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Completed

46 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

120 enrolled 8 charts

Uveal Melanoma

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Phase 2 Completed

89 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00559949 2017-01-30

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Phase 2 Completed

39 enrolled 8 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT00553332 2016-04-22

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

29 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT00888134 2016-01-15

Selumetinib in Cancers With BRAF Mutations

Phase 2 Completed

28 enrolled 9 charts

Adult Solid Neoplasm

NCT01206140 2015-10-05

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Phase 2 Completed

70 enrolled 8 charts

Sarcoma

NCT01085214 2015-08-19

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Phase 2 Completed

37 enrolled 9 charts

Multiple Myeloma

NCT00866177 2015-08-11

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

167 enrolled 6 charts

Melanoma

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Melanoma

NCT00604721 2014-05-28

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

19 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2 Terminated

4 enrolled 7 charts

Melanoma